(Q46650427)

24 December 2017

title

The bioequivalence of telithromycin administered orally as crushed tablets versus tablets swallowed whole (English)

1 reference

24 December 2017

0 references

Christina Lippert

1

1 reference

24 December 2017

Seth Gbenado

2

1 reference

24 December 2017

Chunfu Qiu

3

1 reference

24 December 2017

Bruce Lavin

4

1 reference

24 December 2017

Steven J Kovacs

5

1 reference

24 December 2017

publication date

1 September 2005

1 reference

24 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

24 December 2017

volume

45

1 reference

24 December 2017

issue

9

1 reference

24 December 2017

page(s)

1025-1031

1 reference

24 December 2017

Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Ketolides-telithromycin, an example of a new class of antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Tissue kinetics of telithromycin, the first ketolide antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Pneumonia in the long-term-care facility

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005279273

21 January 2018

Identifiers

DOI

10.1177/0091270005279273

1 reference

24 December 2017

1 reference

24 December 2017